Min-Xuan Wang

Ms. Min-Xuan Wang

Universal Stabilization Technologies, Inc.
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2021 in npj Vaccines
Verified
Journal Article
Open access
PDF file
JLJasmina Luczo
Jasmina Luczo
TBTatiana Bousse
Tatiana Bousse
SJScott K. Johnson
Scott K. Johnson
CJCheryl A. Jones
Cheryl A. Jones
NPNicholas Pearce
Nicholas Pearce
Stephen Mark TompkinsStephen Mark Tompkins
Stephen Mark Tompkins
Influenza viruses cause annual seasonal epidemics and sporadic pandemics; vaccination is the most effective countermeasure. Intranasal live attenuated influenza vaccines (LAIVs) are needle-free, mimic the natural route of infection, and elicit robust immunity. However, some LAIVs require reconstitution and cold-chain requirements restrict storage and distribution of all influenza vaccines. We generated a dry-powder, thermostable LAIV (T-LAIV) using Preservation by Vaporization technology and assessed the stability, immunogenicity, and efficacy of T-LAIV alone or combined with delta inulin adjuvant (Advax™) in ferrets. Stability assays demonstrated minimal loss of T-LAIV titer when stored at 25 °C for 1 year. Vaccination of ferrets with T-LAIV alone or with delta inulin adjuvant elicited mucosal antibody and robust serum HI responses in ferrets, and was protective against homologous challenge. These results suggest that the Preservation by Vaporization-generated dry-powder vaccines could be distributed without refrigeration and administered without reconstitution or injection. Given these significant advantages for vaccine distribution and delivery, further research is warranted.

30 April 2021 in Vaccines
Verified
Journal Article
Open access
PDF file
CHCasey Hensley
Casey Hensley
PZPeng Zhou
Peng Zhou
SSSofia Schnur
Sofia Schnur
HMHassan Mahsoub
Hassan Mahsoub
YLYu Liang
Yu Liang
VBVictor Bronshtein
Victor Bronshtein
Difficulties related to storage and transport of currently available live oral rotavirus vaccines can have detrimental consequences on the efficacy of the vaccines. Thus, there is a great need for thermostable vaccines that can eliminate the necessity for cold chain storage or reconstitution before administration. In this study, we developed a dissolvable oral polymeric film comprised of a live attenuated thermostable tetravalent rhesus-human reassortant rotavirus vaccine (RRV-TV) powder and antacid (CaCO3). Immunogenicity and protective efficacy of the vaccine after buccal delivery was evaluated in the gnotobiotic pig model of human rotavirus (HRV) infection and diarrhea. Two doses of the vaccine were highly immunogenic and conferred strong protection against virus shedding and diarrhea upon challenge with a high dose of a virulent G1 HRV in gnotobiotic pigs. Those pigs vaccinated with the preserved film vaccine had significantly delayed onset of diarrhea; reduced duration and area under the curve of diarrhea; delayed onset of fecal virus shedding; and reduced duration and peak of fecal virus shedding titers compared to pigs in both the placebo and the reconstituted liquid oral RRV-TV vaccine groups. Associated with the strong protection, high titers of serum virus neutralization antibodies against each of the four RRV-TV mono-reassortants and G1 HRV-specific serum IgA and IgG antibodies, as well as intestinal IgA antibodies, were induced by the preserved film vaccine. These results demonstrated the effectiveness of our thermostable buccal film rotavirus vaccine and warrant further investigation into the promise of the novel technology in addressing drawbacks of the current live oral HRV vaccines.

31 July 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
DHDawne Rowe Haas
Dawne Rowe Haas
SJScott K. Johnson
Scott K. Johnson
CJCheryl A. Jones
Cheryl A. Jones
MWMin-Xuan Wang
Min-Xuan Wang
EMErin A. Miller
Erin A. Miller
Stephen Mark TompkinsStephen Mark Tompkins
Stephen Mark Tompkins
Live Attenuated Influenza Vaccines (LAIV) are attenuated, temperature sensitive, and cold adapted to limit replication to the upper respiratory tract. This modification seeks to prevent clinical disease while effectively eliciting the development of immunity. While LAIVs offer benefits over Inactivated Influenza Vaccines (IIV), thermostability remains a key concern. Using Preservation By Vaporization (PBV), we have established a thermostable LAIV (tLAIV) that is stable at ambient temperature for at least one year and suitable for respiratory delivery in a dry powder form. Using the ferret model, we have demonstrated that tLAIV elicited protective immune responses to subsequent influenza virus infection. Here, we expand on these studies to confirm the safety of tLAIV following intranasal administration. Continuing with the ferret model, we completed a dose-response safety and immunogenicity study of tLAIV formulated both with and without Advax adjuvant and compared the results to those of liquid LAIV controls. Dry-powder vaccination with tLAIV or LAIV did not cause significant temperature elevations, lethargy, weight loss, or other clinical changes. Clinical chemistry and complete blood counts (CBC) remained within established baseline reference ranges. On histopathology, there were no adverse effects seen on the upper or lower respiratory tract 14 days after vaccine delivery. ELISA and hemagglutination inhibition assays (HAI) confirmed seroconversion was induced by all vaccine formulations, with neither dose nor adjuvant improving the magnitude of response. Nasal wash analysis demonstrated that PBV- stabilized tLAIV exhibited comparable infectivity to the same dose of liquid LAIV control. These findings further reinforce the similarity in infectivity, immunogenicity, and safety of intranasal vaccination using PBV-tLAIV, both with and without an adjuvant.